What is Leerink Partnrs’ Estimate for RAPT FY2024 Earnings?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a research report issued to clients and investors on Monday, November 11th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($2.72) for the year, down from their previous forecast of ($2.52). The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at ($1.19) EPS and FY2028 earnings at ($1.33) EPS.

RAPT has been the subject of a number of other research reports. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $8.00 to $2.00 in a report on Monday. UBS Group decreased their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research report on Monday, September 9th. Wells Fargo & Company cut their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday. HC Wainwright restated a “neutral” rating on shares of RAPT Therapeutics in a report on Tuesday. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday. One analyst has rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $13.00.

RAPT Therapeutics Stock Down 9.8 %

Shares of RAPT opened at $1.57 on Thursday. The business has a 50-day simple moving average of $1.96 and a two-hundred day simple moving average of $3.05. RAPT Therapeutics has a 12-month low of $1.31 and a 12-month high of $27.35. The stock has a market cap of $54.79 million, a PE ratio of -0.57 and a beta of 0.33.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new stake in RAPT Therapeutics in the 1st quarter valued at about $97,000. EntryPoint Capital LLC purchased a new position in RAPT Therapeutics during the 1st quarter worth $161,000. XTX Topco Ltd purchased a new stake in RAPT Therapeutics in the 2nd quarter valued at about $108,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of RAPT Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after buying an additional 3,824 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in shares of RAPT Therapeutics by 66.2% in the second quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock valued at $258,000 after acquiring an additional 33,692 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.